Money
Filter News
Found 83,198 articles
-
Burning Rock Announces Receipt of Notification from NASDAQ - Jan 04, 2024
1/4/2024
Burning Rock Biotech Limited announced that it has received written notification from the staff of the Listing Qualifications Department of the Nasdaq Stock Market LLC dated December 29, 2023, indicating that for the last 30 consecutive business days, the closing bid price for the Company’s American depositary shares was below the minimum bid price of US$1.00 per share requirement set forth in NASDAQ Listing Rule 5450.
-
Longboard Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
1/4/2024
Longboard Pharmaceuticals, Inc. announced the pricing of an upsized underwritten public offering of 10,000,000 shares of its voting common stock at a price to the public of $21.00 per share.
-
Keros Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
1/4/2024
Keros Therapeutics, Inc. announced the pricing of an underwritten public offering of 3,500,000 shares of common stock, at a public offering price of $40.00 per share.
-
SELLAS Life Sciences Announces Proposed Public Offering - Jan 04, 2024
1/4/2024
SELLAS Life Sciences Group, Inc. announced that it intends to offer and sell shares of its common stock and warrants to purchase shares of common stock in a public offering.
-
Rapport Therapeutics tops this year’s list with $250 million in Series A and B financing in just six months. -
The money will be funneled into early- to mid-stage therapeutic companies with “multi-asset portfolios” for the “next generation” of biotechs in addition to diagnostic and life sciences tools. -
2024 Predictions for Biotech M&As
1/3/2024
Continued fallout from the IRA, heightened antitrust enforcement and the rise of AI will all shape the first wave of biotech mergers and acquisitions coming this year, experts tell BioSpace. -
Tome Biosciences has only been on the scene for a short time but on Tuesday notched an acquisition of CRISPR-based biotech Replace Therapeutics for $65 million upfront. -
ABVC BioPharma and its Subsidiary Receive $460M From AiBtl BioPharma as the First Milestone Payment of Global Licensing Fees
1/3/2024
ABVC BioPharma, Inc. and its subsidiary BioLite, Inc. announced that the Company and its subsidiary received an aggregate of 46 million shares from AiBtl BioPharma Inc., as its first milestone payment under a global licensing agreement.
-
Vasa Therapeutics Announces Closing of Seed Financing to Advance Novel Therapies for Diseases of Cardiovascular Aging
1/3/2024
Vasa Therapeutics, Inc. announced today the closing of series seed funding led by Orphinic Scientific SA ("Orphinic"), an early-stage investor focused on companies with game-changing potential.
-
Abbott Hosts Conference Call for Fourth-Quarter 2023 Earnings
1/3/2024
Abbott will announce its fourth-quarter 2023 financial results on Wednesday, Jan. 24, before the market opens.
-
STRATA Skin Granted Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement
1/3/2024
STRATA Skin Sciences, Inc. announced that it has received a notification letter from Nasdaq Stock Market LLC that the Company has been granted a 180-day extension, or until June 24, 2024, to regain compliance with Nasdaq’s minimum bid price rule.
-
QurAlis Strengthens Global Presence With Opening of European Headquarters That Includes R&D Manufacturing
1/3/2024
QurAlis Corporation announced the opening of its European Union headquarters in Leiden, The Netherlands.
-
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 03, 2024
1/3/2024
ImmunoGen, Inc. announced that the compensation committee of the Company’s Board of Directors approved, effective as of December 29, 2023, the grant of restricted stock units covering 167,159 shares of ImmunoGen’s common stock under the ImmunoGen, Inc.
-
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 03, 2024
1/3/2024
Cytokinetics, Incorporated announced that on December 29, 2023 it granted stock options to purchase an aggregate of 6,150 shares of common stock to three new employees, whose employment commenced in December 2023, as a material inducement to their employment.
-
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) - Jan 03, 2024
1/3/2024
Terns Pharmaceuticals, Inc. announced that it has granted as of January 1, 2024 an equity inducement award to a new employee under the terms of the 2022 Employment Inducement Award Plan, as amended.
-
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 03, 2024
1/3/2024
BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted eight newly-hired employees stock options to purchase an aggregate of 48,700 shares, and restricted stock units covering an aggregate of 34,000 shares, of BioCryst common stock.
-
OPKO Health Announces Private Offering of Convertible Senior Notes Due 2029
1/3/2024
OPKO Health, Inc. announced that it is commencing a private offering of $200.0 million aggregate principal amount of its Convertible Senior Notes due 2029.
-
Dyne Therapeutics Announces Proposed Public Offering of Common Stock - Jan 03, 2024
1/3/2024
Dyne Therapeutics, Inc. announced that it has commenced an underwritten public offering of $175,000,000 of shares of its common stock.
-
Celularity Announces Net Sales and Total Revenue Expectations for Fourth Quarter 2023 and Full Year 2023
1/3/2024
Celularity Inc. announced expected net sales of its advance biomaterial products and biobanking businesses for the fourth quarter 2023 and the full year 2023 and expected total revenue for the fourth quarter 2023 and the full year 2023.